Standard DAPT

PreclinicalSmall molecule

YYonsei University

Standard DAPT is one of 84 small molecule programs targeting Acute Coronary Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Coronary SyndromeActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

Acute Coronary SyndromePreclinical

Active, not recruiting

Acute Myocardial InfarctionPreclinical

Active, not recruiting

Competition

Competitive Landscape

75 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Brilinta

AstraZeneca

Approved

8 2

Repatha

Amgen

Approved

3 3

Bayer Aspirin

Bayer

Approved

2 4

Eliquis

Bristol-Myers Squibb

Approved

1 5

Praluent

Regeneron

Approved

1 6

Avapro

Sanofi

Approved

1 7

Leqvio

Neoral

Zebeta

Aggrastat

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Antiplatelet De-Escalation

NCT06216821

Q3 2029

N/ARecruiting

Dual Antiplatelet Therapy

NCT07198529

Clinical

Trials by Indication[1]

Acute Myocardial Infarction1 trial

Evaluation of a Modified Anti-Platelet Therapy Associated With Low-dose DES Firehawk in Acute Myocardial Infarction Patients Treated With Complete Revascularization Strategy

Completed·MMicroPort CRM·N/A·NCT04753749·2,248 enrolled

Antiplatelet De-escalation1 trial

OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time

Recruiting·SShenyang Northern Hospital·N/A·NCT06216821·3,490 enrolled

Dual Antiplatelet Therapy1 trial

OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina

Recruiting·KKorea University Guro Hospital·N/A·NCT07198529·130 enrolled

Acute Coronary Syndrome1 trial

Ticagrelor Monotherapy in PAtients Treated With New-generation Drug-eluting Stents for Acute Coronary Syndrome; T-PASS Trial

Unknown status·YYonsei University·N/A·NCT03797651·2,850 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Standard DAPT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard DAPT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard DAPT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYonsei University

Standard DAPT

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Acute Myocardial Infarction1 trial

Antiplatelet De-escalation1 trial

Dual Antiplatelet Therapy1 trial

Acute Coronary Syndrome1 trial

References

Drug Info

Quick Facts

Related News